Orlistat (Ro 18-0647)

Catalog No.S1629 Synonyms: Tetrahydrolipstatin

For research use only.

Orlistat (Ro 18-0647, Tetrahydrolipstatin) is a general lipase inhibitor with IC50 of 122 ng/ml for PL from human duodenal juice. Orlistat treatment reduces proliferation, induces apoptosis and arrests cell cycle.

Orlistat (Ro 18-0647) Chemical Structure

CAS No. 96829-58-2

Selleck's Orlistat (Ro 18-0647) has been cited by 8 Publications

Purity & Quality Control

Choose Selective Lipase Inhibitors

Biological Activity

Description Orlistat (Ro 18-0647, Tetrahydrolipstatin) is a general lipase inhibitor with IC50 of 122 ng/ml for PL from human duodenal juice. Orlistat treatment reduces proliferation, induces apoptosis and arrests cell cycle.
Targets
lipase [1]
(Cell-free assay)
Fatty acid synthesis [1]
(Cell-free assay)
In vitro

Orlistat, an inhibitor of lipases and fatty acid synthase, is used orally for long-term treatment of obesity. Orlistat shows antiproliferative activity against cancer cells in vitro. It has been found to augment pro-apoptotic NOXA protein[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293T MUXGeY5kfGmxbjDhd5NigQ>? NX;PdGplUW6qaXLpeIlwdiCxZjDoeY1idiCGQVfMZYxxcGFiZYjwdoV{e2WmIHnuJGhGUzJ7M2SgZ4VtdCCvZX3idoFv\SC3c3nu[{BcOTSFXWPBS{B{fWK|dILheIUhcW5iZHX0[ZJo\W62IH\y[YUhe2:udYTpc44h[nliRmLFWEBie3OjeTygTWM2OD1yLkCxJO69VQ>? NVm1eIt1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3N|g3OzhpPkKyO|M5PjN6PD;hQi=>
COS M{XTdGZ2dmO2aX;uJIF{e2G7 M{HXc|E2KG2rboO= MVzJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KESDR1zhcJBp[SCneIDy[ZN{\WRiaX6gRYZzcWOjbjDndoVmdiCvb37r[ZkhS0:VIHPlcIx{KHW|aX7nJJNvNTFvc4TlZZJwgWxvMj3bNVREZS2jcnHjbIlld26xeXyt[4x6[2W{b3ygZZMhe3Wkc4TyZZRmKGmwY4XiZZRm\CCob4KgNVUhdWmwczDifUBj\XSjIHPveY51cW6pIHHuZYx6e2m|LDDJR|UxKD1iMD6wNFEh|ryPLh?= M4W4UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUG3NlIyLz5{NkmxO|IzOTxxYU6=
COS7 M3\hfWZ2dmO2aX;uJIF{e2G7 NGnybmszOCCvaX7z NX;4TZA4UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDIUEBmgHC{ZYPz[YQhcW5iQ1;TO{Bk\WyuczD1d4lv\yCSRVStRVEh[2:wdHHpcolv\yCGTWDHJJZme2mlbHXzJIF{KHO3YoP0doF1\SCycnX0doVifGWmIH\vdkAzOCCvaX7zJIZwdGyxd3XkJIJ6KHO3YoP0doF1\SCjZHTpeIlwdiCjbnSgcYVie3W{ZXSg[ZZmenliMkCgd4VkeyCob4KgNVAhdWmwczDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjByMzFOwG0v NEPJRWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|ME[xN|M{Pyd-M{C2NVM{Ozd:L3G+
HT1080 M2rsdWZ2dmO2aX;uJIF{e2G7 NXLzS5lrOjBibXnudy=> NYS0WGVMUW6qaXLpeIlwdiCxZjDlcoRwfGinbHnhcEBtcXCjc3WgbY4hcHWvYX6gTHQyODhyIHPlcIx{KHW|aX7nJHBGTC2DMTDjc451[WmwaX7nJGROWEdidnXzbYNt\XNiYYOgd5Vje3S{YYTlJJBz\XS{ZXH0[YQh\m:{IEKwJI1qdnNiZn;scI94\WRiYomgd5Vje3S{YYTlJIFl\Gm2aX;uJIFv\CCvZXHzeZJm\CCndnXyfUAzOCC|ZXPzJIZweiBzMDDtbY5{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNFA3KM7:TT6= MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODZzM{OzO{c,OzB4MUOzN|c9N2F-
HEK293F MUDGeY5kfGmxbjDhd5NigQ>? NVPCS5lSOjBibXnudy=> NHzOdnZKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIGDMJIV5eHKnc4Pl[EBqdiCKRVuyPVNHKGOnbHzzJJV{cW6pIGDFSE1COSClb370ZYlvcW6pIFTNVGchfmW|aXPs[ZMh[XNic4Xid5Rz[XSnIIDy[ZRz\WG2ZXSg[o9zKDJyIH3pcpMh\m:ubH;3[YQh[nlic4Xid5Rz[XSnIHHk[Il1cW:wIHHu[EBu\WG|dYLl[EBmfmW{eTCyNEB{\WO|IH\vdkAyOCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwMEC2JO69VS5? M1r0SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNkGzN|M4Lz5|ME[xN|M{PzxxYU6=
HEK293 NF;hSIJHfW6ldHnvckBie3OjeR?= M1nXdFEhfU1? MUixNEBucW6| NY\KeolIUW6qaXLpeIlwdiCxZjDoeY1idiCDQljEOkBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIF1KDFidV2gdJJmNWmwY4XiZZRm\CCob4KgNVAhdWmwczDi[YZwemViMj3BS{B{fWK|dILheIUh[WSmaYTpc44h\m:ubH;3[YQh[nlicnHwbYQhPDBiZn;s[EBkd22yb4Xu[EBlcWy3dHnvckBu\WG|dYLl[EBi\nSncjCxNEBucW6|IHL5JGhRVENibXX0bI9lNCCLQ{WwJF0hOC5yMUOxPEDPxE1w MmXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|NES1PVYoRjJ4M{S0OVk3RC:jPh?=
HEK293 MX7GeY5kfGmxbjDhd5NigQ>? M1\VdVEhfU1? M1LiO|ExKG2rboO= MVjJcohq[mm2aX;uJI9nKGi3bXHuJGFDUER4IHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYSgNUB2VSCycnWtbY5kfWKjdHXkJIZweiBzMDDtbY5{KGKnZn;y[UAzNUGJIIP1ZpN1emG2ZTDh[IRqfGmxbjDmc4xtd3enZDDifUBz[XCrZDC0NEBnd2ymIHPvcZBwfW6mIHTpcJV1cW:wIH3lZZN2emWmIHHmeIVzKDNyIH3pcpMh[nliSGDMR{Bu\XSqb3SsJGlEPTBiPTCwMlAyPDF|IN88UU4> NHXKc2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO0OFU6Pid-Mk[zOFQ2QTZ:L3G+
HEK293 NWfz[IpkTnWwY4Tpc44h[XO|YYm= M2r2cFEhfU1? NYGzd4M2OTBibXnudy=> NFnHWmtKdmirYnn0bY9vKG:oIHj1cYFvKEGESFS2JIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZZQhOSC3TTDwdoUucW6ldXLheIVlKG[xcjCxNEBucW6|IHLl[o9z\SB{LVHHJJN2[nO2cnH0[UBi\GSrdHnvckBnd2yub4fl[EBjgSC{YYDp[EA1OCCob3zkJINwdXCxdX7kJIRqdHW2aX;uJI1m[XO3cnXkJIFnfGW{IE[wJI1qdnNiYomgTHBNSyCvZYToc4QtKEmFNUCgQUAxNjBzOUm1JO69VS5? M1rYSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{S0OVk3Lz5{NkO0OFU6PjxxYU6=
N18TG2 M4LFVWZ2dmO2aX;uJIF{e2G7 M2HrWVIxKG2rboO= MWHJcohq[mm2aX;uJI9nKESDR1zhcJBp[SCrbjDtc5V{\SCQMUjUS|Ih[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDpc45wdXmlaX6tbY5lfWOnZDDmc5Ju[XSrb36gc4YhOi2DRzDpcoN2[mG2ZXSg[o9zKDJyIH3pcpMh[nliTFOtUXMh[W6jbInzbZMtKEmFNUCgQUAxNjB{IN88UU4> MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjlzN{KyNUc,OjZ7MUeyNlE9N2F-
HEK293T NI[wPYpHfW6ldHnvckBie3OjeR?= NXz4fGFTUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBDSVR3IITyZY5{\mWldHXkJIlvKEiHS{K5N3Qh[2WubIOgZpkhW0SVLWDBS2UhfXOrbnegdohw\GGvaX7lMZRi\2enZDDGVEBxem:kZTygTWM2OCB;IECuNFMh|ryPLh?= NETvcng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[1O|k4OSd-MUi2OVc6PzF:L3G+
HEK293 NWDOT49XTnWwY4Tpc44h[XO|YYm= MXSxJJVO NY[4enZXOTBibXnudy=> NFfZV5hKdmirYnn0bY9vKG:oIHj1cYFvKEGESFS2JIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZZQhOSC3TTDwdoUucW6ldXLheIVlKG[xcjCxNEBucW6|IHLl[o9z\SB{LVHHJJN2[nO2cnH0[UBi\GSrdHnvckBnd2yub4fl[EBjgSC{YYDp[EA1OCCob3zkJINwdXCxdX7kJIRqdHW2aX;uJI1m[XO3cnXkJIFnfGW{IEmwJI1qdnNiYomgTHBNSyCvZYToc4QtKEmFNUCgQUAxNjB|N{G1JO69VS5? M{PYUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{S0OVk3Lz5{NkO0OFU6PjxxYU6=
HEK293 NUPSdW57TnWwY4Tpc44h[XO|YYm= NHO5R21KdmirYnn0bY9vKG:oIHj1cYFvKEGESFS2JINwdnSjaX7pcocheEOPVk[tRWMucEGESFS2JJRz[W6|ZnXjeIVlKGmwdH:gTGVMOjl|IHPlcIx{NCCLQ{WwJF0hOC5yNEe4OkDPxE1w MnSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUK5PFIoRjJ3N{WyPVgzRC:jPh?=
HEK293 MnzJSpVv[3Srb36gZZN{[Xl? NYnRU4NtUW6qaXLpeIlwdiCxZjDoeY1idiCDQljEOkBkd262YXnubY5oKHCFTW[2MWFENWiDQljEOkB1emGwc3\lZ5Rm\CCrboTvJGhGUzJ7MzDj[YxteyxiSVO1NEA:KDBwMES4JO69VS5? NXH0doxlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVI6QDJpPkK1O|UzQTh{PD;hQi=>
HEK293T NVHoOo5uTnWwY4Tpc44h[XO|YYm= MVfJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IGDMRVJoPyC2cnHud4Zm[3SnZDDpckBJTUt{OUPUJINmdGy|IHL5JHNFWy2SQVfFJJV{cW6pIILoc4RidWmwZT30ZYdo\WRiRmCgdJJw[mVuIFnDOVAhRSByLkC1JO69VS5? NFLvSYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[1O|k4OSd-MUi2OVc6PzF:L3G+
COS7 MUHGeY5kfGmxbjDhd5NigQ>? NV7IZXRTUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDERWdN[WyyaHGgc5ZmemW6cILld5Nm\CCrbjDh[pJq[2GwIHfy[YVvKG2xbnvlfUBEV1N5IHPlcIx{NCCLQ{WwJF0hOC5yNjFOwG0v MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ3N{m3NUc,OTh4NUe5O|E9N2F-
COS7 M{HsfWZ2dmO2aX;uJIF{e2G7 NV\lRYVPUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDERWdN[mW2YTDveoVz\XiycnXzd4VlKGmwIHHmdolk[W5iZ4Ll[Y4hdW:wa3X5JGNQWzdiY3XscJMtKEmFNUCgQUAxNjB4IN88UU4> NXHEd5NoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2OVc6PzFpPkG4OlU4QTdzPD;hQi=>
COS7 M2jOdmZ2dmO2aX;uJIF{e2G7 M4LQNFIxKG2rboO= NYixRZR[UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDMVGwh\XiycnXzd4VlKGmwIFPPV|ch[2WubIOgeZNqdmdiUFXEMWEyKGOxboThbY5qdmdiRF3QS{B3\XOrY3zld{BieyC|dXLzeJJifGVicILleJJm[XSnZDDmc5IhOjBibXnud{Bnd2yub4fl[EBjgSC|dXLzeJJifGViYXTkbZRqd25iYX7kJI1m[XO3cnXkJIV3\XK7IEKwJJNm[3NiZn;yJFExKG2rboOgZpkh\my3b4Lld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC5yNk[g{txONg>? Ml;VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB4MUOzN|coRjNyNkGzN|M4RC:jPh?=
HEK293T NELreotHfW6ldHnvckBie3OjeR?= NVLTemxIUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBCSkiGMUKgeJJidnOoZXP0[YQhcW5iSFXLNlk{XCClZXzsd{BjgSCVRGOtVGFITSC3c3nu[{BzcG:mYX3pcoUufGGpZ3XkJGZRKHC{b3LlMEBKSzVyIE2gNE4xQCEQvF2u NXjCdVljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2OVc6PzFpPkG4OlU4QTdzPD;hQi=>
HEK293 MVfGeY5kfGmxbjDhd5NigQ>? NGKwUIRKdmirYnn0bY9vKG:oIHj1cYFvKEGESFSxNkBkd262YXnubY5oKHCFTW[2MXhNPC2qQVLISFEzKHS{YX7z[oVkfGWmIHnueI8hUEWNMkmzJINmdGy|LDDJR|UxKD1iMD6xPUDPxE1w MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3Mkm4Nkc,OjV5NUK5PFI9N2F-
HEK293 NX3tcIlpTnWwY4Tpc44h[XO|YYm= MUixNEBucW6| NEDTdGdKdmirYnn0bY9vKG:oIHj1cYFvKEGESFSxNkBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJJBz\S2rbnP1ZoF1\WRiZn;yJFExKG2rboOgZoVnd3KnIEKtRWche3Wkc4TyZZRmKGGmZHn0bY9vKGK7IFjQUGMhdWW2aH;kMEBKSzVyIE2gNE4yQSEQvF2u NULM[YR3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOFQ2QTZpPkK2N|Q1PTl4PD;hQi=>
HEK293 M{jnUWZ2dmO2aX;uJIF{e2G7 NYjtdmRmUW6qaXLpeIlwdiCxZjDoeY1idiCDQljENVIh[2:wdHHpcolv\yCyQ13WOk1ZVDRvaFHCTGQyOiC2cnHud4Zm[3SnZDDpcpRwKEiHS{K5N{Bk\WyuczygTWM2OCB;IECuNVkxPTVizszNMi=> NUnXfoFTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVI6QDJpPkK1O|UzQTh{PD;hQi=>
HEK293 M1jQPWZ2dmO2aX;uJIF{e2G7 MnPDNVAhdWmwcx?= NF\xTFlKdmirYnn0bY9vKG:oIHj1cYFvKEGESFSxNkBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJJBz\S2rbnP1ZoF1\WRiZn;yJFExKG2rboOgZoVnd3KnIEKtRWche3Wkc4TyZZRmKGGmZHn0bY9vKGK7IFjQUGMhdWW2aH;kMEBKSzVyIE2gNE4yQTB3NTFOwG0v MoPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|NES1PVYoRjJ4M{S0OVk3RC:jPh?=
HEK293 NXv2N5JKTnWwY4Tpc44h[XO|YYm= NWfKe2tbTGm|cHzhZ4Vu\W62IH;mJHs{UF2FUD21OVk1OCCocn;tJIh2dWGwIILlZ49u[mmwYX70JGNDOSC{ZXPldJRweiCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEurIE2gNk42KM7:TT6= M{PHU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OEOxOVc3Lz5zOEizNVU4PjxxYU6=
BxPC3 M1LaUWZ2dmO2aX;uJIF{e2G7 M2rHUVExKHSxIEG0JIRigXN? NGD2T21KdmirYnn0bY9vKG:oIIP1dpZqfmGuIH;mJIh2dWGwIFL4VGM{KGOnbHzzJIFnfGW{IEGwJJRwKDF2IHThfZMh[nliY4L5d5RidCC4aX;s[ZQhe3SjaX7pcocu[mG|ZXSgZ49td267IH\vdo1ifGmxbjDhd5NigSxiSVO1NEA:KDhwNEWg{txONg>? Mlu1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MUO3NVIoRjJ3NUGzO|EzRC:jPh?=
MDA-MB-231 MmfXR5l1d3SxeHnjbZR6KGG|c3H5 MkjrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJktKEmFNUCgQUAyOyEQvF2u M1LsclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUSxN|c{Lz5{OUW0NVM4OzxxYU6=
MDA-MB-435 NH7Fe4VEgXSxdH;4bYNqfHliYYPzZZk> M3vNbFQ5KGi{cx?= NFnad|FEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFM2KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDD[YxtKHSrdHXyJIF{e2G7LDDJR|UxKD1iMU[uPEDPxE1w Mm\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh5MUCyNVAoRjF6N{GwNlExRC:jPh?=
HepG2 (DPX-2) NYOwbYZkTnWwY4Tpc44h[XO|YYm= MVyyOEBpenN? MnHsRYN1cX[jdHnvckBw\iCqdX3hckBRYFJiZYjwdoV{e2WmIHnuJIh2dWGwIFjldGczKCiGUGitNkkh[2WubIOgZZN{\XO|ZXSgZZMhcW6mdXP0bY9vKG:oIFPZVFNCPCCjZoTldkAzPCCqcoOgZpkhdHWvaX7ld4NmdnRiYX7hcJl{cXNuIFXDOVAhRSB{OD6yJO69VS5? NFS1UYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEm2OlA1Oyd-MkC5OlYxPDN:L3G+
COS7 MmXtSpVv[3Srb36gZZN{[Xl? NE\QcmFKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGRCT0ykZYThJI93\XKneIDy[ZN{\WRiaX6gZYZzcWOjbjDndoVmdiCvb37r[ZkhS0:VNzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44hd2ZiMj3hdoFkcGmmb37vfYxodHmlZYLvcEBjgSCZZYP0[ZJvKGKub4T0bY5o NGPEco89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[1O|k4OSd-MUi2OVc6PzF:L3G+
COS7 NILJOZpHfW6ldHnvckBie3OjeR?= NXzFfZpvUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBFSUeOYXzwbIEhd3[ncnX4dJJme3OnZDDpckBi\nKrY3HuJIdz\WWwIH3vcotmgSCFT2O3JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjCyMYFz[WOqaXTvco96dGeueXPldo9tKGK7IGfld5Rmem5iYnzveJRqdmd? Ml;1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4NUe5O|EoRjF6NkW3PVcyRC:jPh?=
MDA-MB-435 Mn\VRZBweHSxc3nzJIF{e2G7 M{TDdVI2KHWP NXy0ZpFNPzJiaILz M{PQXmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTVTBMW1DNTR|NTDj[YxteyCjc4Pld5Nm\CCjczDEUmEh\nKjZ33lcpRifGmxbjDheEAzPSC3TTDh[pRmeiB5MjDodpM> NYrMZopyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi3NVAzOTBpPkG4O|ExOjFyPD;hQi=>
HEK293 NYXXcItiTnWwY4Tpc44h[XO|YYm= NX[zTmxpOSC3TR?= MXmxNEBucW6| MlXmVoV3\XK|aXLs[UBqdmirYnn0bY9vKG:oIHj1cYFvKEGESFS2JIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZZQhOSC3TTDwdoUucW6ldXLheIVlKG[xcjCxNEBucW6|IHLl[o9z\SB{LVHHJJN2[nO2cnH0[UBi\GSrdHnvckBnd2yub4fl[EBjgSC{YYDp[EA1OCCob3zkJINwdXCxdX7kJIRqdHW2aX;uJI1m[XO3cnXkJIFnfGW{IEGwJJRwKDlyIH3pcpMh[nliSGDMR{Bu\XSqb3S= MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN2NEW5Okc,OjZ|NES1PVY9N2F-
LNCAP NHj0cnZHfW6ldHnvckBie3OjeR?= NVjBdYpMOjBidV2= M3Ln[|Q5KGi{cx?= MXfJcoR2[3Srb36gc4Yh[2ixbHXzeIVzd2xibXX0ZYJwdGm|bTDk[ZJm\3WuYYTpc44hcW5iaIXtZY4hVE6FQWCgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKE6ERD3jbI9t\XO2ZYLvcEB2eHSja3WgZZQhOjBidV2gZYZ1\XJiNEigbJJ{KGK7IFTBVGkwSWyneHGg[ox2d3JiNkOzJJBp[Wyub3nkbY4he3SjaX7pcoch[mG|ZXSgbIlocC2lb370[Y51KGmvYXfpcoch[W6jbInzbZM> NVu0PZBDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0O|QxPzFpPkK5OFc1ODdzPD;hQi=>
BV2 MX\GeY5kfGmxbjDhd5NigQ>? NUXr[WtLOzBibXnudy=> M3\lOWlvcGmkaYTpc44hd2ZiQVLISFYhcW5ibX;1d4UhSlZ{IHPlcIx{KHC{ZXnuZ5Vj[XSnZDDmc5IhOzBibXnud{BidmRic4Xid4VyfWWwdDDh[IRqfGmxbjDv[kBcO0ifLUKtU2che3Wkc4TyZZRmKG2nYYP1doVlKGGodHXyJFE2KG2rboOgZpkhdGmzdXnkJJNkcW62aXzsZZRqd25iY3;1cpRqdmdibXX0bI9l MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6NEi2NUc,Ojh{OES4OlE9N2F-
BV2 MV3GeY5kfGmxbjDhd5NigQ>? M334RVMxKG2rboO= M1XDXGlvcGmkaYTpc44hd2ZiQVLISFEzKGmwIH3veZNmKEKYMjDj[YxteyCycnXpcoN2[mG2ZXSg[o9zKDNyIH3pcpMh[W6mIIP1ZpNmeXWnboSgZYRlcXSrb36gc4YhYzOKXT2yMW9IKHO3YoP0doF1\SCvZXHzeZJm\CCjZoTldkAyPSCvaX7zJIJ6KGyrcYXp[EB{[2mwdHnscIF1cW:wIHPveY51cW6pIH3leIhw\A>? M{HI[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6Mki0PFYyLz5{OEK4OFg3OTxxYU6=
Assay
Methods Test Index PMID
Western blot FASN / AR / p-AKT / p-p53 / p53 / VEGF / Cyclin D1 / Bcl-2 / Cleaved caspase-3 31527721
Growth inhibition assay Cell viability 28387458
In vivo Orlistat, administered by oral route, is minimally absorbed by the gastrointestinal tract and is able to prevent the absorption of a large percentage of lipids, thereby reducing lipid supply from outside sources[1]. Because of its extremely low oral bioavailability, the effects of Orlistat are largely confined to the gastrointestinal tract, where it inactivates pancreatic lipase. Therefore, the formulation and route of delivery would have to be changed to treat tumors of the breast, prostate, and so on. Orlistat halts tumor cell proliferation, induces tumor cell apoptosis, and inhibits the growth of PC-3 tumors in nude mice. A pharmacokinetic analysis of Orlistat (155 mg/kg) administered by i.p. injection showed peak blood levels to be ∼10 μM 2 h after dosing (data not shown). Beyond this time, blood levels of the drug decayed rapidly[2].

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: Jurkat CD4+ T cell leukemia cell line
  • Concentrations: 2.5, 5, 10, 20, 40 μM
  • Incubation Time: 2 days
  • Method:

    Leukemic cells were cultured in the presence of graded concentrations of orlistat for two days. Control cultures were exposed to DMSO alone at the concentration corresponding to that utilized for orlistat 40 μM. At the end of the in vitro treatment, leukemic cells were lysed and subjected to western blot (WB) analysis.

Animal Research:

[2]

  • Animal Models: Nude mice (PC-3 xenograft tumor)
  • Dosages: 240 mg/kg/day
  • Administration: i.p.

Solubility (25°C)

In vitro

DMSO 99 mg/mL
(199.7 mM)
Water Insoluble
Ethanol '99 mg/mL

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.

13mg/mL

Chemical Information

Molecular Weight 495.73
Formula

C29H53NO5

CAS No. 96829-58-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01755676 Completed Drug: Orlistat 60 mg|Other: Placebo Obesity EMS September 2016 Phase 3
NCT02141230 Withdrawn Drug: Alli® 60 mg Weight Loss GlaxoSmithKline|Hamell December 2015 Not Applicable
NCT01719419 Withdrawn Drug: Placebo|Drug: Orlistat Overweight Pennington Biomedical Research Center March 2012 Not Applicable
NCT01332448 Completed Drug: Orlistat 120|Drug: Orlistat 60 Obesity GlaxoSmithKline February 2010 --
NCT01414465 Completed Drug: Orlistat Overweight University of Campinas Brazil|Germed Pharma October 2009 Not Applicable
NCT01170806 Completed Drug: Orlistat Obesity University of Campinas Brazil|Germed Pharma October 2009 Not Applicable

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Orlistat (Ro 18-0647) | Orlistat (Ro 18-0647) supplier | purchase Orlistat (Ro 18-0647) | Orlistat (Ro 18-0647) cost | Orlistat (Ro 18-0647) manufacturer | order Orlistat (Ro 18-0647) | Orlistat (Ro 18-0647) distributor